Australia markets close in 4 hours 39 minutes

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.30+0.14 (+2.27%)
At close: 04:00PM EDT
6.25 -0.05 (-0.79%)
After hours: 07:26PM EDT

Bioventus Inc.

4721 Emperor Boulevard
Suite 100
Durham, NC 27703
United States
919 474 6700
https://www.bioventus.com

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees995

Key executives

NameTitlePayExercisedYear born
Mr. Mark L. SingletonSenior VP & CFO740.04kN/A1970
Mr. Anthony D'AdamioSenior VP, General Counsel & Corporate Secretary705.38kN/A1961
Mr. Robert E. ClaypoolePresident, CEO & DirectorN/AN/A1972
Mr. Mike Crowe B.S., M.B.A.Senior Vice President of OperationsN/AN/AN/A
Mr. David CrawfordVice President of Investor Relations & TreasurerN/AN/AN/A
Ms. Katrina J. Church J.D.Senior VP & Chief Compliance OfficerN/AN/A1962
Ms. Helen LeupoldSenior VP & Chief Human Resources OfficerN/AN/AN/A
Mr. Larry ChenManaging Director of China & Asia PacificN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Corporate governance

Bioventus Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.